Dr. Reddy’s Signs Biosimilars Pact in TurkeyBy
Dr. Reddy's Laboratories Ltd. has formed a strategic partnership with TR-Pharm, an Istanbul, Turkey-based pharmaceutical company, involving three biosimilar products. A total of three products will be registered and subsequently commercialized as a part of this agreement by TR-Pharm in Turkey. TR-Pharm will also manufacture the drug substance and drug product upon completion of its facility investment.
TR-Pharm has begun laying out the groundwork for the technology transfer. This collaboration will be an important component of TR-Pharm's ongoing biological product development and manufacturing business in the region.
TRPharm focuses on the launch of new and innovative medicines starting from registration and accomplishment of clinical programs in all phases, as well as building a biotech manufacturing facility in Turkey for the supply of monoclonal antibodies to the Commonweath of Independent States (CIS) countries and the Middle East and North African (MENA) region besides the local Turkish market. TRPharm’s product portfolio includes products for oncology, virology, inflammatory and rare diseases.
Source: Dr. Reddy’s Laboratories.